Project Oncology®

In recent years, doctors have become interested in how large language models and AI technologies could potentially improve radiology overall. Even though these technologies are still in the beginning stages of being used in medicine, eventually doctors hope to show what impact they could have on patients. To learn more about these new technologies and imaging agents, join Dr. Tyler Bradshaw, Assistant Professor in the Department of Radiology at the University of Wisconsin-Madison, who presented this topic at the SNMMI 2024 Annual Meeting.

Advocacy is rooted in patients telling their stories, and every patient can be an advocate to help and allow others to hear about their experience. This has also helped clinicians get the medicine they need for their patients. Dive in to hear how you can incorporate advocacy strategies into your practice with Dr. Ashley Sumrall, Neuro- and Medical Oncologist, Hematologist, and Associate Professor at Atrium Health in Charlotte, North Carolina at the Levine Cancer Institute.

If we want to ensure that we and our patients have healthcare when we’re older and it continues to be available, it’s important to take a stand and be a part of advocacy work. There are multiple ways to get involved, and it’s not as intimidating as someone might think, so to share some of these strategies and the impact it could have on the future of healthcare, join Dr. Ashely Sumrall, Medical Oncologist, Hematologist, and Associate Professor at Atrium Health in Charlotte, North Carolina at the Levine Cancer Institute.

This video brief will discuss quality improvement in myelofibrosis management. To highlight ways to improve care for patients with both primary and secondary myelofibrosis, we’ll examine the experiences of two cancer centers that engaged in quality improvement programs.

• Molecular Testing
• Symptom Assessment
• Prognostic Risk Assessment
• JAK Inhibitor Therapy
• Shared Decision-Making
• Interprofessional Team-Based Care Coordination

Tune in ahead of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting in Toronto for a preview of what to expect with Dr. Munir Ghesani, Chief Medical Officer and the Medical Director at United Theranostics in Princeton, New Jersey.

Head and neck cancers are the seventh most common cancers globally and are increasing in prevalence.1,2 To dive further into the intricacies of this early-stage cancer, join Dr. Lori Wirth, Medical Oncologist in the Head and Neck Oncology Program at Massachusetts General Hospital in Boston.

References:

1. Gormley M, et al. Br Dent J. 2022;233(9):780-786.
2. Barsouk A, et al. Med Sci (Basel). 2023;11(2):42.

©2024 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved.
EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada.
US-NONO-00581 05/2024

The results from the phase III EMERALD trial led to the approval of ORSERDU® (elacestrant) as the first oral selective estrogen receptor degrader for ER-positive/HER2-negative metastatic breast cancer patients with ESR1 mutations after disease progression following at least one line of endocrine therapy.1 But given the results from prior analyses, clinicians wanted to better understand the data for elacestrant in subgroups of patients with key clinical or biomarker characteristics, and so a post hoc analysis of elacestrant in these subgroups who typically have a poorer prognosis was conducted. Explore the EMERALD trial and the key outcomes from this subgroup analysis with Dr. Jennifer Caudle and medical oncologist Dr. Joyce O'Shaughnessy.

A poster presented at the 2024 American Association for Cancer Research Annual Meeting showcased findings from the ASCEND 2 study, which examined the performance of a multi-cancer early detection (MCED) test design that included methylation and protein biomarkers. The study found that this test design achieved overall sensitivity of 50.9 percent for all cancers at a high specificity of 98.5 percent. Dive further into these results and what they might mean for early cancer detection with Dr. Brian McDonough and Dr. Frank Diehl, Senior Vice President of Multi Cancer Early Detection at Exact Sciences Corporation.

The addition of antibody-drug conjugate (ADC) therapies to the treatment armamentarium for endocrine-refractory, HR-positive, HER2-negative metastatic breast cancer has greatly improved outcomes for patients in this setting. However, selecting the appropriate ADC and determining the optimal sequencing of these therapies may be challenging. In this activity, expert faculty in the field of breast cancer review the clinical burden related to endocrine-refractory disease, the role of ADCs in this setting, and best practices for the sequencing of these agents.

In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.